AIM: The survival rate of patients with stomach cancer isused to evaluate the effects of treatments.The short- andmid-term survival of patients on the present level of treatmentscan be described by calculating 1- to 5-year survival rates.The aims of this study were to document patterns of survivalafter treatments for stomach cancer in Changle city and analyzewhether the stage of cancer and the way of treatmentimpacted on survival of patients or not.METHODS: A total number of 745 patients with stomachcancer reported in the Changle Cancer Registry from 1993to 1998 were investigated with respect to the diseasecondition,the way of treatment and survival time.1- to 5-year survival rates were estimated by using life-tablemethod.RESULTS: The 1- to 5-year survival rates in the patientswith stomach cancer in Changle city were 54.23%,41.77%,37.95%,33.98% and 30.47%,respectively.The 1- to 5-yearsurvival rates in stageIor Ⅱ group were 3,6.1,7.4,8.9and 9.8 times as high as those in stage Ⅲ or Ⅳ group,respectively.The 1- to 5-year survival rates in operationgroup were 3.5,8.7,11.2,11.7 and 19 times as high as thosein no operation group,respectively.For the patients with stageⅢ or Ⅳ stomach cancer the 1-year survival rate in operationgroup was 3 times as high as that in no operation group and 2-year survival rate in operation group was 11.9 times as high asthat in no operation group.For the patients with stage Ⅲ or Ⅳstomach cancer,the differences of the survival rates averagesurvival times between total gastrectomy and partialgastrectomy were not significant and the median survival timesin these 2 groups were 8 mo and 9 mo,respectively.CONCLUSION: Mid-term survival rates of patients withstomach cancer in Changle city are low.Stage of cancer isan important factor influencing survival of patients withstomach cancer.Surgery is an effective treatment for thepatients with stage Ⅳ cancer and can raise short- andmid-term survival rates.Total gastrectomy should not beencouraged for the patients with late stage of cancer. AIM: The survival rate of patients with stomach cancer isused to evaluate the effects of treatments. The short- and mid-term survival of patients on the present level of treatmentscan be described by calculating 1- to 5-year survival rates.The aims of this study were to document patterns of survivalafter treatments for stomach cancer in Changle city and analyze whether the stage of cancer and the way of treatmentimpacted on survival of patients or not. METHODS: A total number of 745 patients with stomach cancer reported in the Changle Cancer Registry from 1993 to 1998 were investigated with respect to the disease condition, the way of treatment and survival time. 1- to 5-year survival rates were estimated by using life-tablemethods .RESULTS: The 1- to 5-year survival rates in the patients with stomach cancer in Changle cities were 54.23%, 41.77%, 37.95%, 33.98% and 30.47% respectively. The 1- to 5-yearurvival rates in stage II group were 3, 6.1, 7.4, 8.9 and 9.8 times as high as those in stage III or group, respectively. The 1- to 5-year survival rates in operation groups were 3.5, 8.7, 11.2, 11.7 and 19 times as high as those in no operation group, respectively. For the patients with stage III or IV stomach cancer the 1-year survival rate in operation group was 3 times as high as that in no operation group and 2-year survival rate in operation group was 11.9 times as high asthat in no operation group. For the patients with stage III or Ⅳstomach cancer, the differences of the survival rates averagesurvival times between total gastrectomy and partialgastrectomy were not significant and the median survival times in these 2 groups were 8 months and 9 months, respectively.CONCLUSION: Mid-term survival rates of patients with cancer in Changle city are low. Stage of cancer isan important factor influencing survival of patients with gastric cancer. Surgery is an effective treatment for the patients with stage IV cancer and can raise short- and mid-term survival rates. Total gastrectomy should not been cough raged for the ppatients with late stage of cancer.